Illumina, Inc.
ILMN
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables useā¦ read more
Healthcare
Diagnostics & Research
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$206.45
Price+2.57%
$5.18
1Y
Price
Market Cap
$31.236b
Large
Price/Earnings 3y Avg5y Avg
41x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+28.5%
EBITDA Margin+17.9%
Net Profit Margin+13.9%
Free Cash Flow Margin+28.5%
EBITDA Margin+17.9%
Net Profit Margin+13.9%
Free Cash Flow MarginRevenue
$4.493b
+3.6%
1y CAGR+0.0%
3y CAGR-0.5%
5y CAGREarnings
$825m
-2.9%
1y CAGR+53.7%
3y CAGR+58.7%
5y CAGREPS
$5.36
-1.6%
1y CAGR+54.9%
3y CAGR+59.6%
5y CAGRBook Value
$2.838b
$6.650b
Assets$3.812b
Liabilities$2.527b
DebtDebt to Assets
38.0%
1.8x
Debt to EBITDAFree Cash Flow
$939m
+0.9%
1y CAGR+61.2%
3y CAGR+87.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company